杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/08/31 | 1,766 | 1,776 | 1,765 | 1,774 | +5 | +0.3% | 159,500 |
2023/08/30 | 1,769 | 1,778 | 1,763 | 1,769 | -1 | -0.1% | 74,900 |
2023/08/29 | 1,749 | 1,770 | 1,748 | 1,770 | +21 | +1.2% | 75,500 |
2023/08/28 | 1,755 | 1,758 | 1,745 | 1,749 | +4 | +0.2% | 32,400 |
2023/08/25 | 1,736 | 1,753 | 1,732 | 1,745 | +6 | +0.3% | 92,000 |
2023/08/24 | 1,731 | 1,745 | 1,727 | 1,739 | -1 | -0.1% | 42,500 |
2023/08/23 | 1,724 | 1,743 | 1,724 | 1,740 | +4 | +0.2% | 45,300 |
2023/08/22 | 1,735 | 1,741 | 1,725 | 1,736 | +2 | +0.1% | 52,100 |
2023/08/21 | 1,734 | 1,741 | 1,728 | 1,734 | +6 | +0.3% | 50,500 |
2023/08/18 | 1,711 | 1,729 | 1,710 | 1,728 | +15 | +0.9% | 62,300 |
2023/08/17 | 1,728 | 1,731 | 1,712 | 1,713 | -15 | -0.9% | 103,900 |
2023/08/16 | 1,732 | 1,735 | 1,718 | 1,728 | -16 | -0.9% | 114,100 |
2023/08/15 | 1,746 | 1,750 | 1,733 | 1,744 | -13 | -0.7% | 113,400 |
2023/08/14 | 1,783 | 1,790 | 1,756 | 1,757 | -24 | -1.3% | 69,500 |
2023/08/10 | 1,761 | 1,781 | 1,756 | 1,781 | +20 | +1.1% | 54,700 |
2023/08/09 | 1,750 | 1,764 | 1,737 | 1,761 | +11 | +0.6% | 49,900 |
2023/08/08 | 1,730 | 1,755 | 1,730 | 1,750 | +21 | +1.2% | 63,400 |
2023/08/07 | 1,707 | 1,738 | 1,707 | 1,729 | +19 | +1.1% | 57,800 |
2023/08/04 | 1,730 | 1,730 | 1,705 | 1,710 | -25 | -1.4% | 112,700 |
2023/08/03 | 1,775 | 1,775 | 1,721 | 1,735 | -73 | -4% | 193,600 |
2023/08/02 | 1,800 | 1,813 | 1,795 | 1,808 | +6 | +0.3% | 142,700 |
2023/08/01 | 1,784 | 1,802 | 1,782 | 1,802 | +29 | +1.6% | 150,000 |
2023/07/31 | 1,795 | 1,803 | 1,767 | 1,773 | -7 | -0.4% | 101,100 |
2023/07/28 | 1,761 | 1,785 | 1,760 | 1,780 | +3 | +0.2% | 104,000 |
2023/07/27 | 1,767 | 1,777 | 1,759 | 1,777 | +1 | +0.1% | 46,900 |
2023/07/26 | 1,760 | 1,778 | 1,758 | 1,776 | +12 | +0.7% | 59,200 |
2023/07/25 | 1,770 | 1,774 | 1,759 | 1,764 | -6 | -0.3% | 62,700 |
2023/07/24 | 1,755 | 1,770 | 1,749 | 1,770 | +19 | +1.1% | 67,000 |
2023/07/21 | 1,747 | 1,751 | 1,738 | 1,751 | +16 | +0.9% | 63,700 |
2023/07/20 | 1,747 | 1,751 | 1,732 | 1,735 | -14 | -0.8% | 40,400 |
2023/07/19 | 1,746 | 1,749 | 1,735 | 1,749 | +16 | +0.9% | 60,800 |
2023/07/18 | 1,713 | 1,734 | 1,713 | 1,733 | +16 | +0.9% | 42,400 |
2023/07/14 | 1,718 | 1,724 | 1,706 | 1,717 | +3 | +0.2% | 62,900 |
2023/07/13 | 1,719 | 1,722 | 1,704 | 1,714 | +1 | +0.1% | 73,900 |
2023/07/12 | 1,708 | 1,717 | 1,706 | 1,713 | +10 | +0.6% | 79,600 |
2023/07/11 | 1,730 | 1,732 | 1,700 | 1,703 | -16 | -0.9% | 79,400 |
2023/07/10 | 1,722 | 1,727 | 1,714 | 1,719 | -3 | -0.2% | 82,200 |
2023/07/07 | 1,728 | 1,735 | 1,718 | 1,722 | -6 | -0.3% | 148,900 |
2023/07/06 | 1,749 | 1,750 | 1,715 | 1,728 | -20 | -1.1% | 130,100 |
2023/07/05 | 1,728 | 1,750 | 1,727 | 1,748 | +16 | +0.9% | 68,400 |
2023/07/04 | 1,745 | 1,751 | 1,732 | 1,732 | -29 | -1.6% | 105,300 |
2023/07/03 | 1,755 | 1,772 | 1,754 | 1,761 | +10 | +0.6% | 59,800 |
2023/06/30 | 1,757 | 1,758 | 1,740 | 1,751 | -5 | -0.3% | 85,500 |
2023/06/29 | 1,766 | 1,775 | 1,751 | 1,756 | -11 | -0.6% | 68,800 |
2023/06/28 | 1,748 | 1,767 | 1,746 | 1,767 | +19 | +1.1% | 80,900 |
2023/06/27 | 1,758 | 1,760 | 1,735 | 1,748 | -20 | -1.1% | 76,900 |
2023/06/26 | 1,780 | 1,781 | 1,756 | 1,768 | -5 | -0.3% | 80,200 |
2023/06/23 | 1,788 | 1,788 | 1,767 | 1,773 | -11 | -0.6% | 119,700 |
2023/06/22 | 1,768 | 1,787 | 1,768 | 1,784 | +16 | +0.9% | 92,600 |
2023/06/21 | 1,772 | 1,786 | 1,766 | 1,768 | +4 | +0.2% | 124,000 |
301~
350
件表示中 / 3585件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 149,100円 | +3.2% | +4.5% | 3.49% | 17.13倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ゼリア新薬 | 222,100円 | +13.6% | +29.2% | 2.07% | 11.52倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ネクセラファーマ | 113,700円 | +197.7% | - | 0.00% | 46.47倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
JCRファーマ | 69,600円 | -3.7% | -36.7% | 2.87% | 22.92倍 | 1.50倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
栄研化 | 210,100円 | +0.4% | -8.4% | 2.52% | 27.77倍 | 1.58倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム